COVID-19 - RECCE® 327 & RECCE® 529
The highly contagious respiratory disease, COVID-19 continues to spread throughout the world and with hundreds of millions of cases and over four million deaths, the devastating health and economic impact continues to surge.
In response to the COVID-19 pandemic, Recce has expanded its infectious disease research to better understand how its synthetic anti-infectives may work against SARS-CoV-2, the virus that causes COVID-19, and subsequent bacterial co-infections.
About RECCE® 327 & RECCE® 529
Recce leveraged its anti-infective technology to develop RECCE® 529 (R529), a new synthetic polymer formulation with indications against viruses.
With the addition of this new formulation, R529 and RECCE® 327 (R327) are being evaluated against SARS-CoV-2.
As a new class, synthetic polymer drugs may be effective against other deadly superbugs, beyond those are bacterial in origin, including viruses. R327 has exhibited efficacy against the Influenza A virus, enveloped viruses that are causative agents of respiratory disease.
The genome of the Influenza A viruses comprises single-stranded ribonucleic acid (ssRNA) molecules – similar to that of coronaviruses. Coronaviruses, including SARS-CoV-2, are also enveloped viruses that have caused widespread respiratory disease.
|Asset Route of administration||Indications||Discovery||Preclinical||Phase I||Phase II||Phase III||Next data readout||Market Size|
|R327 Nasal||COVID & Influenza||
|R529 IV and Intranasal||COVID||